136 related articles for article (PubMed ID: 12435859)
1. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
3. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
Kawakami M; Kawakami K; Puri RK
Int J Cancer; 2003 Jan; 103(1):45-52. PubMed ID: 12455052
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR; Puri RK
Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
7. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
8. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
Kawakami K; Husain SR; Bright RK; Puri RK
Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model.
Kawakami K; Kawakami M; Puri RK
Clin Cancer Res; 2004 Aug; 10(15):5264-70. PubMed ID: 15297430
[TBL] [Abstract][Full Text] [Related]
11. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
Kawakami K; Joshi BH; Puri RK
Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
[TBL] [Abstract][Full Text] [Related]
13. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
14. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
[TBL] [Abstract][Full Text] [Related]
15. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
16. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.
Kawakami M; Kawakami K; Puri RK
Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421
[TBL] [Abstract][Full Text] [Related]
18. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
19. IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice.
Blease K; Jakubzick C; Schuh JM; Joshi BH; Puri RK; Hogaboam CM
J Immunol; 2001 Dec; 167(11):6583-92. PubMed ID: 11714828
[TBL] [Abstract][Full Text] [Related]
20. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
